Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer [Phase 1]
An update indicates that a Phase 1 study of TVB-2640 in men with metastatic castration-resistant prostate cancer is currently recruiting.
-
CLINICAL_TRIALS research · 2025-11-19Clinical Trial Update: PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer [Phase 1]
A Phase 1 trial is evaluating PSCA-targeting CAR-T cells with or without radiation in patients with PSCA-expressing metastatic castration-re…
-
CLINICAL_TRIALS research · 2025-11-19Clinical Trial Update: Memantine Hydrochloride in Prostate Cancer Patients [Phase 2]
A Phase 2 clinical trial evaluating memantine hydrochloride in metastatic castration-resistant prostate cancer and other prostate cancers, c…
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors [Phase 2]
Phase 2 clinical trial evaluating pacritinib in metastatic castration-resistant prostate cancer that progressed after prior androgen recepto…
-
CLINICAL_TRIALS research · 2025-11-04Clinical Trial Update: Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC [Phase 2]
This clinical trial update describes a Phase 2 study evaluating sipuleucel-T in combination with Bipolar Androgen Therapy for metastatic cas…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-11-04Clinical Trial Update: Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide [Phase 2]
Phase 2 clinical trial evaluating the effect of androgen receptor–directed therapies (darolutamide or enzalutamide) on cognitive function in…
-
CLINICAL_TRIALS research · 2025-10-31Clinical Trial Update: Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 1]
This is a Phase 1 dose-escalation trial evaluating cabozantinib in combination with Lutetium-177 PSMA-617 for metastatic castration-resistan…
-
CLINICAL_TRIALS research · 2025-10-21Clinical Trial Update: Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects [Phase 2]
This is a Phase 2 clinical trial update evaluating Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone plus Olaparib in patients wit…
-
CLINICAL_TRIALS research · 2025-10-16Clinical Trial Update: A Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) [Phase 1, Phase 2]
A Phase 1/2 clinical trial of HLD-0915 for metastatic castration-resistant prostate cancer is currently recruiting.
-
CLINICAL_TRIALS research · 2025-10-15Clinical Trial Update: ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
This ClinicalTrials.gov update describes the ARCTIC study from Duke University, a prospective set of trials investigating liquid biomarkers …
-
CLINICAL_TRIALS research · 2025-10-10Clinical Trial Update: Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors [Phase 1]
Phase 1 study evaluating OP-3136 in advanced or metastatic solid tumors, including ER-positive/HER2-negative breast cancer, non-small cell l…
-
CLINICAL_TRIALS research · 2025-10-10Clinical Trial Update: Imaging of Solid Tumors Using DLL3 SPECT [EARLY_Phase 1]
Early Phase 1 clinical trial evaluating DLL3 SPECT imaging for solid tumors, including castration-resistant prostate cancer and neuroendocri…
-
CLINICAL_TRIALS research · 2025-10-01Clinical Trial Update: Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial [Phase 3]
Phase 3 RECIPROCAL trial examines different dosing schedules of Lutetium-177 Lu-PSMA radioligand therapy in advanced prostate cancer; the st…
-
CLINICAL_TRIALS research · 2025-09-19Clinical Trial Update: A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones [Phase 1]
This clinical trial update describes a Phase 1 study evaluating how Radium-223 distributes in the body of men with bone-metastatic castratio…
-
CLINICAL_TRIALS research · 2025-09-19Clinical Trial Update: Phase III Radium 223 mCRPC-PEACE III [Phase 3]
Phase III Radium-223 mCRPC-PEACE III trial for metastatic castration-resistant prostate cancer is currently listed as active but not recruit…
-
CLINICAL_TRIALS research · 2025-09-18Clinical Trial Update: Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC) [Phase 2]
Phase 2 clinical trial evaluating Sacituzumab Tirumotecan in combination with Tagitanlimab for aggressive variant and neuroendocrine prostat…
-
CLINICAL_TRIALS research · 2025-09-17Clinical Trial Update: The COSMYC Trial (COmbined Suppression of MYC) [Phase 2]
The COSMYC trial (Combined Suppression of MYC) is a Phase 2 study in metastatic castration-resistant prostate cancer that is currently recru…
-
CLINICAL_TRIALS research · 2025-09-09Clinical Trial Update: A Study of NX-1607 in Adults With Advanced Malignancies [Phase 1]
A Phase 1 study evaluating NX-1607 in adults with advanced malignancies is actively recruiting across multiple tumor types, including ovaria…
-
CLINICAL_TRIALS research · 2025-09-09Clinical Trial Update: Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2) [Phase 1]
This is a Phase 1 trial (PRODIGY-2) evaluating personalized versus fixed-activity 177Lu-PSMA-617 radiopharmaceutical therapy for metastatic …
-
CLINICAL_TRIALS research · 2025-09-05Clinical Trial Update: Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer [Phase 2]
A Phase 2 clinical trial compares stereotactic body radiotherapy to standard of care for oligoprogressive metastatic prostate cancer, curren…
-
CLINICAL_TRIALS research · 2025-09-04Clinical Trial Update: A Novel Insight Into CRPC Progression and Immune: Evidence From Single-cell Spatial Transcriptome Multi-omics
A clinical trial from Anhui Medical University aims to study castration-resistant prostate cancer progression and immune interactions in met…
-
CLINICAL_TRIALS research · 2025-08-27Clinical Trial Update: Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T [Phase 2]
A Phase 2 clinical trial is evaluating treating metastatic castration-resistant prostate cancer with PROVENGE (sipuleucel-T) plus one infusi…
-
CLINICAL_TRIALS research · 2025-08-27Clinical Trial Update: Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer [Phase 2]
A Phase 2 clinical trial comparing cabazitaxel with or without carboplatin to 177Lu-PSMA-617 in metastatic castration-resistant prostate can…
-
CLINICAL_TRIALS research · 2025-08-27Clinical Trial Update: FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer [Phase 1, Phase 2]
ClinicalTrials.gov update describes a Phase 1/2 trial of FOR46 in combination with enzalutamide for metastatic castration-resistant prostate…
-
CLINICAL_TRIALS research · 2025-08-27Clinical Trial Update: A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC [Phase 2]
A Phase II clinical trial evaluating the safety, efficacy, and pharmacokinetics of YL201 in metastatic castration-resistant prostate cancer …